Zacks: Analysts Expect Kura Oncology Inc (KURA) Will Announce Earnings of -$0.41 Per Share
Wall Street brokerages expect that Kura Oncology Inc (NASDAQ:KURA) will post ($0.41) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kura Oncology’s earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.43). Kura Oncology posted earnings of ($0.38) per share during the same quarter last year, which indicates a negative year over year growth rate of 7.9%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 6th.
According to Zacks, analysts expect that Kura Oncology will report full-year earnings of ($1.73) per share for the current fiscal year, with EPS estimates ranging from ($1.77) to ($1.70). For the next financial year, analysts expect that the firm will post earnings of ($2.08) per share, with EPS estimates ranging from ($2.95) to ($1.85). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Kura Oncology.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, August 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.45).
Kura Oncology stock opened at $17.15 on Tuesday. The stock has a market cap of $660.77 million, a P/E ratio of -11.28 and a beta of 4.14. Kura Oncology has a 52 week low of $11.40 and a 52 week high of $24.02. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.22 and a quick ratio of 10.22.
A number of institutional investors have recently bought and sold shares of KURA. Victory Capital Management Inc. purchased a new stake in Kura Oncology during the 2nd quarter worth about $27,104,000. Eagle Asset Management Inc. purchased a new stake in Kura Oncology in the 2nd quarter valued at about $24,881,000. Carillon Tower Advisers Inc. purchased a new stake in Kura Oncology in the 2nd quarter valued at about $16,853,000. BlackRock Inc. grew its holdings in Kura Oncology by 25.5% in the 2nd quarter. BlackRock Inc. now owns 2,002,265 shares of the company’s stock valued at $36,440,000 after buying an additional 406,963 shares during the period. Finally, Sphera Funds Management LTD. purchased a new stake in Kura Oncology in the 1st quarter valued at about $6,188,000. Hedge funds and other institutional investors own 77.42% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
See Also: Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.